DGAP-News: Evotec SE / Key word(s): AGM/EGM
Evotec SE virtual Annual General Meeting 2021 approves all proposed agenda items
2021-06-15 / 17:20
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
. ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY
. DR CONSTANZE ULMER-EILFORT ELECTED AS NEW MEMBER OF THE SUPERVISORY BOARD
. PROF. DR WOLFGANG PLISCHKE RESIGNS FROM HIS OFFICE AS CHAIRMAN OF THE SUPERVISORY BOARD
Hamburg, Germany, 15 June 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its shareholders
approved all proposals the Company's Management put to vote at the Company's virtual Annual General Meeting 2021 with
the required majority. Due to the COVID-19 pandemic, this year's Annual General Meeting again was held as a purely
virtual event.
First, CEO Dr. Werner Lanthaler and CFO Enno Spillner presented Evotec SE's new strategic direction - the "Action Plan
2025" - as well as the business development and highlights of the fiscal year 2020.
All actions of the Management Board and the Supervisory Board were approved by the Annual General Meeting 2021 for the
fiscal year 2020. Furthermore, the shareholders confirmed the appointment of Ernst & Young GmbH
Wirtschaftsprüfungsgesellschaft, Hamburg, as auditors for the fiscal year 2021.
The Annual General Meeting also elected a new member of the Supervisory Board: Effective immediately, Dr Constanze
Ulmer-Eilfort will become a new member of the Supervisory Board of Evotec SE. Dr Constanze Ulmer-Eilfort has been a
partner in the Munich office of the law firm Baker McKenzie for more than 20 years and has been a member of the Global
Executive Committee for several years. She has long-term and extensive experience in advising high-tech, pharmaceutical
and media companies on the protection and marketing of their intellectual property rights and on a wide range of
agreements, including cooperation and licensing agreements, R&D agreements and agreements with academic institutions.
The long-standing Chairman of the Supervisory Board, Prof. Dr Wolfgang Plischke, resigned from his office for personal
reasons. As confirmed by the Supervisory Board today following the Annual General Meeting, the former vice chairperson
Prof. Dr Iris Löw-Friedrich will initially become the new Chairwoman of the Supervisory Board.
"I would like to express my sincere thanks, also on behalf of my colleagues on the Evotec Management Board, to our
long-standing Supervisory Board Chairman Prof. Dr Wolfgang Plischke for the great cooperation over the last seven
years. We always appreciated his very qualified advice and constructive feedback. At the same time, I would like to
warmly welcome Dr Ulmer-Eilfort to the Supervisory Board of Evotec SE. I look forward to working with her," said Dr
Werner Lanthaler, Chief Executive Officer of Evotec.
Prof. Dr Wolfgang Plischke, former Chairman of the Supervisory Board of Evotec SE, said: "Due to personal reasons I
have made the decision to resign from my office in the Supervisory Board of Evotec SE, effective as of the end of the
ordinary Annual General Meeting 2021. Over the past seven years, I have thoroughly enjoyed working together with my
colleagues in the Supervisory Board and also the close and without exception constructive collaboration with Evotec's
entire Management Board. I am particularly glad to be initially succeeded in my office by Prof. Dr Iris Löw-Friedrich,
a colleague who has served in Evotec's Supervisory Board for as long as I have and who knows the Company extremely
well. Additionally, with the appointment of Dr Constanze Ulmer-Eilfort, Evotec's Supervisory Board gains a proven
expert in the protection of intellectual property - which is an eminently important area for the Company. I look
forward to following Evotec's continued successful development with great interest in the future".
Likewise, the shareholders approved with the required majority the cancellation of the Authorised Capital 2017 and the
creation of a new authorised capital (Authorised Capital 2021) in the amount of 20% of the Company's share capital (now
10% due to the legally binding voluntary self-restriction) with the possibility to exclude shareholders' subscription
rights.
The new remuneration systems of the Management Board and the Supervisory Board were also approved.
In total, 65.17% of the registered share capital was present at the virtual Annual General Meeting 2021.
More information on the Company's Annual General Meeting including the voting results on all agenda items can be found
on the Company's website at https://www.evotec.com/en/invest/annual-general-meeting.
ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop
highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a
unique combination of innovative technologies, data and science for the discovery, development, and production of
first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for
proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies,
academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of
currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious
diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative
therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early
discovery to clinical development. Evotec operates globally with more than 3,700 highly qualified people. The Company's
14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For
additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this
press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ
materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on which any such statement is based.
IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com
=----------------------------------------------------------------------------------------------------------------------
2021-06-15 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
=----------------------------------------------------------------------------------------------------------------------
Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf,
Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1208331
End of News DGAP News Service
=------------
1208331 2021-06-15
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1208331&application_name=news
(END) Dow Jones Newswires
June 15, 2021 11:21 ET (15:21 GMT)